Literature DB >> 32638565

MiR-1165-3p Suppresses Th2 Differentiation via Targeting IL-13 and PPM1A in a Mouse Model of Allergic Airway Inflammation.

Zhengxia Wang1, Ningfei Ji1, Zhongqi Chen1, Zhixiao Sun1, Chaojie Wu1, Wenqing Yu1,2, Fan Hu3, Mao Huang4, Mingshun Zhang5,6.   

Abstract

PURPOSE: CD4⁺T cells are essential in the pathogenesis of allergic asthma. We have previously demonstrated that microRNA-1165-3p (miR-1165-3p) was significantly reduced in T-helper type (Th) 2 cells and that miR-1165-3p was a surrogate marker for atopic asthma. Little is known about the mechanisms of miR-1165-3p in the regulation of Th2-dominated allergic inflammation. We aimed to investigate the associations between Th2 differentiation and miR-1165b-3p in asthma as well as the possible mechanisms.
METHODS: CD4⁺ naïve T cells were differentiated into Th1 or Th2 cells in vitro. MiR-1165-3p was up-regulated or down-regulated using lentiviral systems during Th1/Th2 differentiation. In vivo, the lentiviral particles with the miR-1165-3p enhancer were administered by tail vein injection on the first day of a house dust mite -induced allergic airway inflammation model. Allergic inflammation and Th1/Th2 differentiation were routinely monitored. To investigate the potential targets of miR-1165-3p, biotin-microRNA pull-down products were sequenced, and the candidates were further verified with a dual-luciferase reporter assay. The roles of a target protein phosphatase, Mg2+/Mn2+-dependent 1A (PPM1A), in Th2 cell differentiation and allergic asthma were further explored. Plasma PPM1A was determined by ELISA in 18 subjects with asthma and 20 controls.
RESULTS: The lentivirus encoding miR-1165-3p suppressed Th2-cell differentiation in vitro. In contrast, miR-1165-3p silencing promoted Th2-cell development. In the HDM-induced model of allergic airway inflammation, miR-1165-3p up-regulation was accompanied by reduced airway hyper-responsiveness, serum immunoglobulin E, airway inflammation and Th2-cell polarization. IL-13 and PPM1A were the direct targets of miR-1165-3p. The expression of IL-13 or PPM1A was inversely correlated with that of miR-1165-3p. PPM1A regulated the signal transducer and activator of transcription and AKT signaling pathways during Th2 differentiation. Moreover, plasma PPM1A was significantly increased in asthmatic patients.
CONCLUSIONS: MiR-1165-3p negatively may regulate Th2-cell differentiation by targeting IL-13 and PPM1A in allergic airway inflammation.
Copyright © 2020 The Korean Academy of Asthma, Allergy and Clinical Immunology · The Korean Academy of Pediatric Allergy and Respiratory Disease.

Entities:  

Keywords:  IL-13; MicrdoRNA; Th2; allergy; asthma; inflammation

Year:  2020        PMID: 32638565     DOI: 10.4168/aair.2020.12.5.859

Source DB:  PubMed          Journal:  Allergy Asthma Immunol Res        ISSN: 2092-7355            Impact factor:   5.764


  4 in total

1.  KIF2A decreases IL-33 production and attenuates allergic asthmatic inflammation.

Authors:  Zhengxia Wang; Jingjing Wu; Jingxian Jiang; Qiyun Ma; Meijuan Song; Tingting Xu; Yanan Liu; Zhongqi Chen; Yanmin Bao; Mao Huang; Mingshun Zhang; Ningfei Ji
Journal:  Allergy Asthma Clin Immunol       Date:  2022-06-19       Impact factor: 3.373

2.  A comprehensive analysis of microRNAs as diagnostic biomarkers for asthma.

Authors:  Li Xu; Minhan Yi; Yun Tan; Zixun Yi; Yuan Zhang
Journal:  Ther Adv Respir Dis       Date:  2020 Jan-Dec       Impact factor: 4.031

3.  MicroRNA-21 Inhibition Suppresses Alveolar M2 Macrophages in an Ovalbumin-Induced Allergic Asthma Mice Model.

Authors:  Hwa Young Lee; Jung Hur; Ji Young Kang; Chin Kook Rhee; Sook Young Lee
Journal:  Allergy Asthma Immunol Res       Date:  2021-03       Impact factor: 5.764

Review 4.  Emerging Advances of Non-coding RNAs and Competitive Endogenous RNA Regulatory Networks in Asthma.

Authors:  Xiaoxu Wang; Hui Chen; Jingjing Liu; Linlin Gai; Xinyi Yan; Zhiliang Guo; Fengxia Liu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.